The purpose of this study is to adapt and test a singing intervention that may provide support for breast cancer survivors experiencing stress, anxiety, or depressive symptoms.  THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.  Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

The purpose of this study is to evaluate the safety and tolerability of atacicept in adult and adolescent participants and to measure the effect in reducing proteinuria and preserving renal function.THIS STUDY IS ENROLLING BY INVITATION ONLY

We intend to compare an alternative way of performing cancer surgery for those who have testis cancer. This alternative technique is called extraperitoneal RPLND which has been published in retrospective studies. Its benefits, however, remain to be proved in a prospective study. THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.  Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

This multicenter, randomized, parallel-arm, double-blind, placebo-controlled Phase 3 umbrella- type master protocol aims to create a framework for simultaneously evaluating the safety and efficacy of multiple pharmacologic agents (interventions) for the treatment of high-risk metabolic dysfunction-associated steatotic liver disease.THIS STUDY IS ENROLLING BY INVITATION ONLY - The study team will identify and invite potential participants with MASLD who may also have been diagnosed with type 2 diabetes mellitus (T2DM) to enroll in the study.

This study will evaluate the efficacy and safety of plozasiran in approximately 140 adult participants with severe hypertriglyceridemia (SHTG) and history of at least two prior acute pancreatitis (AP) events not attributed to other etiologies, with at least one occurring within the last 12 months prior to screening. THIS STUDY IS ENROLLING BY INVITATION ONLY

A previous study (25857) focused on developing a multilevel intervention addressing health related variables and other social/structural barriers faced by patients as the most prominent way to acknowledge and improve LT referral equity. The LT-CARE intervention has been designed and as a part of this protocol, will be delivered to and assessed by patients and health care providers.Recruitment for providers: Prospective Provider participants will be from among those who are a GI provider in the state of Indiana. A member of the study staff will call the prospective participant to explain the study in appropriate language. Recruitment for patients: Prospective participants will be referred from their provider or will self-refer from a recruitment flier. A member of the study staff will call the prospective participant to explain the study in appropriate language. At IU Health and Eskenazi sites, prospective participants will be recruited from among those seen in clinic by a Hepatology care provider and will be contacted in person during their clinic appointment. THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.  Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632